- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Axi-cel Demonstrates Long-Term Survival Benefit in Relapsed/Refractory LBCL
April 24th 2022, 3:37pm
Transplantation and Cellular Therapy Meetings
Axicabtagene ciloleucel resulted in a longer overall survival benefit in patients with relapsed or refractory large B-cell lymphoma who did not have event-free survival events at months 12 and 24 vs those who experienced events at these time points.
Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC
April 14th 2022, 5:50pm
Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer, and early results have established the pathway as a prime target for drug development.
Neoadjuvant Chemoimmunotherapy Demonstrates Activity in Advanced Ovarian Cancer
April 13th 2022, 7:30pm
The addition of durvalumab and tremelimumab to chemotherapy led to encouraging responses and a suitable safety profile as neoadjuvant therapy in patients with advanced ovarian cancer, according to findings from the phase 2 KGOG 3046.
Adebrelimab Plus Chemotherapy Improves Survival Vs Chemotherapy Alone in ES-SCLC
April 13th 2022, 2:59pm
The addition of adebrelimab to chemotherapy elicited improved overall survival compared with chemotherapy and placebo in patients with extensive-stage small cell lung cancer.
Pembrolizumab Plus CG0070 Induces Promising Response Rates in BCG-Unresponsive NMIBC
April 13th 2022, 2:55pm
The addition of the selective oncolytic adenovirus CG0070 to pembrolizumab showed encouraging activity and safety in Bacillus Calmette-Guerin–unresponsive non-muscle invasive bladder cancer, according to early data from the phase 2 CORE1 trial.
Frontline Canakinumab Triplet Misses Mark in Advanced NSCLC, But Shows Benefit in Select Subsets
April 13th 2022, 1:40pm
The addition of canakinumab to frontline pembrolizumab and chemotherapy did not improve survival in previously untreated patients with locally advanced or metastatic non–small cell lung cancer. However, signals of activity were seen in patients with a baseline inflammatory biomarker high sensitivity-C-reactive protein.
Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma
April 13th 2022, 1:24pm
The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.
TTX-030 Plus Budigalimab/mFOLFOX6 Induces Responses in PD-L1–Low Advanced Gastric/GEJ Cancer
April 12th 2022, 11:07pm
The addition of the investigational anti-CD39 antibody TTX-030 to frontline treatment with the PD-L1 inhibitor budigalimab and mFOLFOX6 was determined to be safe and tolerable in patients with locally advanced or metastatic HER2-negative gastroesophageal junction adenocarcinoma.
Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma
April 12th 2022, 8:59pm
The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.
BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma
April 12th 2022, 8:30pm
The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.
Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors
April 12th 2022, 7:56pm
Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.
MEDI5752 Demonstrates Intriguing Activity in Advanced Solid Tumors
April 12th 2022, 7:55pm
MEDI5752 treatment led to a dose-dependent increase in peripheral T-cell proliferation and encouraging antitumor activity in patients with advanced solid tumors.
Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors
April 12th 2022, 7:06pm
The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.
Resistance to CAR T-Cell Therapy Predicted by Epigenetic Biomarkers in Pediatric ALL
April 12th 2022, 6:27pm
Resistance to CD19-directed CAR T-cell therapy was associated with molecular characteristics identified in pediatric patients with acute lymphoblastic leukemia.
Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC
April 12th 2022, 12:24pm
Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.
ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma
April 12th 2022, 12:40am
The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.
Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL
April 12th 2022, 12:30am
The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.
gLOH-High Status Is Associated With Enhanced Response to Talazoparib in mCRPC
April 11th 2022, 11:56pm
High genomic loss of heterozygosity scores may serve as a predictive marker for response to treatment with talazoparib in metastatic castration-resistant prostate cancer.
JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
April 11th 2022, 11:18pm
The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 trial.
Combined Immune Pathway Inhibition Improves Responses in Resectable NSCLC
April 11th 2022, 9:25pm
Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.